TABLE 2.
Summary of assay outcomes used to determine the mechanism of action of the indicated compounds against EBOV infection
| Compound | Effecta |
Mechanism of action | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Surface interaction | Uninfected cell no. | Dextran uptake | Transferrin uptake | Effect on EEA1 | Effect on LAMP1 | Acidification block | Cathepsin cleavage | ||
| MLS000078751 | − | + | 0 | 0 | ND | ND | − | 0 | Surface interaction block |
| MLS000394177 | + | 0 | − | 0 | ND | ND | + | 0 | Macropinocytosis block |
| MLS000534476 | − | + | 0 | − | ND | ND | + | 0 | Surface interaction block |
| MLS000554255 | 0 | + | 0 | 0 | + | − | − | 0 | Late endocytic trafficking block |
| MLS000555232 | + | 0 | 0 | 0 | − | − | − | 0 | Early endocytic trafficking block |
| MLS000730532 | 0 | 0 | − | − | ND | ND | + | 0 | Uptake block |
| MLS000733230 | 0 | 0 | − | 0 | ND | ND | + | 0 | Macropinocytosis block |
| MLS000762907 | 0 | 0 | 0 | − | 0 | 0 | + | 0 | Trafficking block |
| MLS001101371 | 0 | 0 | 0 | 0 | 0 | − | + | 0 | Late endocytic trafficking block |
a
0, no effect; +, increase in assay activity; −, decrease in assay activity; ND, not determined.